Coagulation Testing Market Size, Share, Growth, Trends, and Global Industry Analysis: By Product (Clinical laboratory, Automated testing, Semi-automated testing) By Test Type (Automated testing, Semi-automated testing, D-Dimer Testing, Prothrombin Time Testing, Platelet Function Tests, Activated Clotting Time Testing, Anti-Factor Xa Tests, Others), By Technology (Optical Technology, Electrochemical Technology, Mechanical Technology), By Disease Indication (Asthma, Chronic Obstructive Pulmonary Disease (COPD), Pulmonary Arterial Hypertension, Others), By End User (Hospitals and Clinics, Diagnostic Laboratories, Home Care Settings, and Others), and Region Forecast 2021-2032

Coagulation Testing Market size was valued at US$ 1.8 billion in 2025 and is expected to reach US$ 2.9 billion by 2032, growing at a significant CAGR of 6.8% from 2026-2032.  The market comprises diagnostic tests, analyzers, reagents, consumables, and related systems used to evaluate the blood-clotting process and identify abnormalities in hemostasis. These tests help healthcare professionals diagnose and monitor conditions such as bleeding disorders, thrombosis, hemophilia, and other coagulation-related diseases, while also supporting the monitoring of patients receiving anticoagulant therapy.

Key tests include prothrombin time (PT), international normalized ratio (INR), activated partial thromboplastin time (aPTT), fibrinogen testing, D-dimer testing, and platelet-related coagulation assessments. The market serves hospitals, diagnostic laboratories, specialty clinics, research institutions, and point-of-care settings.

Coagulation testing is becoming an increasingly important component of modern diagnostics as healthcare providers focus on faster detection and monitoring of bleeding and thrombotic disorders. Growing anticoagulant use, laboratory automation, point-of-care testing, and advances in coagulation analyzers are reshaping the market. The shift toward rapid and reliable diagnostic results is creating new opportunities for diagnostic companies, analyzer manufacturers, reagent suppliers, hospitals, and clinical laboratories.

Key Developments:

• In June 2025, Sysmex received U.S. FDA 510(k) clearance for its CN-6000 Automated Blood Coagulation Analyzer, together with reagent products supporting PT/INR, APTT, fibrinogen, antithrombin, and D-dimer testing.
• In December 2025, Sysmex launched the CN-700 Automated Blood Coagulation Analyzer in Japan. The compact system incorporates technology from the CN-6000/CN-3000 series and is designed to support automation and testing efficiency, particularly in smaller and medium-sized healthcare facilities.